BioNTech SE (BVMF:B1NT34)

BioNTech SE Income Statement

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Revenue	2,870	2,751	3,819	17,311	18,977
Revenue Growth (YoY)	4.32%	-27.96%	-77.94%	-8.78%	3834.63%
Cost of Revenue	641.8	541.3	599.8	2,995	2,912
Gross Profit	2,228	2,210	3,219	14,316	16,065
Selling, General & Admin	624.4	599	557.7	541.2	327.2
Research & Development	2,105	2,254	1,783	1,537	949.2
Other Operating Expenses	1,088	811.5	293	410	103.4
Operating Income	-1,405	-1,314	690.4	12,643	15,284
Interest Income	423.9	664	519.6	330.3	67.7
Interest Expense	-69.8	-27.4	-23.9	-18.9	-305.1
Total Non-Operating Income (Expense)	354.1	636.6	495.7	311.4	-237.4
Pretax Income	-1,051	-677.7	1,186	12,954	15,046
Provision for Income Taxes	85.3	-12.4	255.8	3,520	4,754
Net Income	-1,136	-665.3	930.3	9,434	10,293
Net Income to Common	-1,136	-665.3	930.3	9,434	10,293
Net Income Growth	-	-	-90.14%	-8.34%	67613.82%
Shares Outstanding (Basic)	242	240	241	243	244
Shares Outstanding (Diluted)	242	240	243	250	260
Shares Change (YoY)	0.54%	-0.95%	-2.84%	-3.81%	4.51%
EPS (Basic)	-4.70	-2.77	3.87	38.78	42.18
EPS (Diluted)	-4.70	-2.77	3.83	37.77	39.63
EPS Growth	-	-	-89.86%	-4.69%	65950.00%
Shares Outstanding	251.33	239.97	237.73	243.22	242.52
Free Cash Flow	280.9	-78.8	5,122	13,248	762.2
Free Cash Flow Growth	-	-	-61.34%	1638.15%	-
Free Cash Flow Per Share	1.16	-0.33	21.10	53.04	2.93
Gross Margin	77.64%	80.32%	84.29%	82.70%	84.66%
Operating Margin	-48.95%	-47.77%	18.08%	73.03%	80.54%
Profit Margin	-39.59%	-24.18%	24.36%	54.50%	54.24%
FCF Margin	9.79%	-2.86%	134.12%	76.53%	4.02%
EBITDA	-1,022	-1,016	873.8	12,766	15,359
EBITDA Margin	-35.61%	-36.94%	22.88%	73.75%	80.94%
EBIT	-1,405	-1,314	690.4	12,643	15,284
EBIT Margin	-48.95%	-47.77%	18.08%	73.03%	80.54%
Effective Tax Rate	-8.12%	1.83%	21.57%	27.17%	31.59%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.